Find a Medicare Part D prescription drug plan for 2027
Medicare Part D
Prescription Drug Coverage 2027
Does Medicare Part D Cover Zepbound in 2027? Sleep Apnea vs. Weight Loss
Reviewed by Russell Noga, Licensed Medicare Insurance Broker (all 50 states) — Last updated November 3, 2026
Medicare Part D plans may cover Zepbound in 2027 for moderate to severe obstructive sleep apnea in adults with obesity, but not for weight loss by itself. Weight-loss use can instead go through the Medicare GLP-1 Bridge for $50 a month, and only the Zepbound KwikPen qualifies there.
2027 by the Numbers
Dec. 20, 2024
date FDA approved Zepbound for obstructive sleep apnea (FDA)
$50
monthly GLP-1 Bridge copay for Zepbound KwikPen weight-loss use (Medicare.gov)
$2,400
2027 out-of-pocket cap that sleep apnea fills count toward (CMS)
Zepbound is Eli Lilly’s brand of tirzepatide for chronic weight management. It has the same active ingredient as Mounjaro, which is approved for type 2 diabetes. In December 2024 the FDA added a second Zepbound use, treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity, and CMS then confirmed that Part D plans are allowed to cover it for that condition.
So for 2027 the question is less about the drug and more about the diagnosis on the prescription. This page covers Zepbound alone. For the wider drug class, see the rules for Wegovy in 2027, its closest competitor.
Key Takeaways
- A sleep apnea diagnosis opens the door to regular Part D coverage; weight loss alone does not.
- People with moderate to severe sleep apnea are not eligible for the Bridge, so their Zepbound must go through the plan.
- The Bridge accepts only the Zepbound KwikPen, not vials or single-dose pens.
- Tirzepatide was not on the list of drugs with Medicare negotiated prices for 2027.
- Our math shows Zepbound billed at list price could reach the $2,400 cap by July.
Three Diagnoses, Three Different Outcomes
| Reason on the prescription | Who may pay in 2027 | Counts toward $2,400 cap? |
|---|---|---|
| Moderate to severe obstructive sleep apnea with obesity | Your Part D plan, if Zepbound is on its formulary | Yes |
| Weight management only | Medicare GLP-1 Bridge, KwikPen form, $50 a month | No |
| Type 2 diabetes | Your plan may cover Mounjaro, the diabetes brand of tirzepatide | Yes |
Coverage depends on the plan and area. Not all plans cover every drug, and plans may list some Zepbound forms but not others.
Central sleep apnea, which has a different cause, is not part of the FDA approval. Zepbound used only to prevent heart disease is also outside the label.
How Plans Review a Sleep Apnea Request
Most plans that list Zepbound for OSA attach prior authorization. The review confirms that the use matches the FDA label before the first fill is paid.
Paperwork a plan may ask the prescriber to send
✔
Sleep study results showing moderate or severe OSA
✔
A recent height and weight showing obesity
✔
Notes that Zepbound is paired with a reduced-calorie diet and more activity
✔
Renewal records later in the year showing the drug is still needed
If the answer is no: Your prescriber can ask the plan for a coverage determination and then an appeal. New enrollees may get a temporary transition supply early in 2027 while the request is reviewed.
The KwikPen Rule Inside the GLP-1 Bridge
The Bridge started July 1, 2026 and CMS extended it through December 31, 2027. It pays for a handful of GLP-1s used for weight reduction and charges the member $50 for a one-month supply. For Zepbound, Medicare’s fact sheet names only the KwikPen, a multi-dose pen that holds four weekly doses.
Accepted by the Bridge
✔
Zepbound KwikPen
✔
One-month fills only
✔
BMI and health criteria met
✔
Approved by Medicare after a prior authorization form
Not accepted by the Bridge
✔
Zepbound vials
✔
Zepbound single-dose pens
✔
Anyone with diabetes, moderate to severe OSA or fatty liver disease
✔
Private fee-for-service, cost plan and PACE members
See plans in your area instantly!
Advertisement
Our 2027 Math for Sleep Apnea Use
| Month | What you pay under the standard benefit | Running total |
|---|---|---|
| January | $700 deductible plus 25% of the rest | $796.68 |
| February to June | $271.68 each month | $2,155.08 |
| July | $244.92, then the cap is met | $2,400.00 |
| August to December | $0 for covered drugs | $2,400.00 |
Our illustration from the CMS 2027 standard benefit ($700 deductible, 25% coinsurance, $2,400 cap) using Zepbound’s list price of about $1,087 a month. A plan’s own negotiated cost is often lower, and copay-based plans differ. Premiums are extra.
July
month the cap is reached
$2,400
most you pay for covered drugs
$600
Bridge total, which never counts
Why Zepbound Has No Negotiated Price Yet
Fifteen drugs get Medicare negotiated prices on January 1, 2027, and semaglutide is one of them. Tirzepatide was not selected because it had not been on the market long enough to qualify. That leaves plan-negotiated rebates as the main price lever for Zepbound in 2027. The program’s rules are covered on our negotiated drug prices 2027 page.
Savings cards and Medicare: Lilly’s cash-pay offers and copay savings cards are generally limited to people without government-funded insurance, so a Part D or Medicare Advantage member usually cannot apply them to plan-covered fills.
Begin Choosing your plan
Advertisement
CALL TO SPEAK WITH A LICENSED INSURANCE AGENT
Advertisement
Announcements That Have Not Taken Effect
1
March 2026. Lilly said Zepbound, Mounjaro and orforglipron would reach participating Part D plans on January 1, 2027 under the BALANCE model.
2
Mid-2026. CMS said BALANCE will not launch in Medicare in 2027 and extended the Bridge instead.
3
Today. No plan-based weight-loss benefit for Zepbound is confirmed for 2027; the Bridge remains the weight-loss route.
If CMS revives BALANCE for a later year, plan rules for Zepbound could change. Until then, treat any report of broad Zepbound weight-loss coverage in 2027 plans as unconfirmed.
Picking a 2027 Plan With Zepbound in Mind
Before you enroll, confirm
✔
Zepbound is on the plan’s 2027 formulary and which forms are listed
✔
The tier, and whether the deductible applies to it
✔
The prior authorization criteria for OSA
✔
Preferred pharmacy pricing in your ZIP code
✔
How your other prescriptions add up toward the cap
The cap, deductible and premium for 2027 are explained on our 2027 out-of-pocket maximum page and the Medicare Part D plans 2027 hub. Exception requests are walked through in the 2027 formulary guide.
The Bottom Line
The Bottom Line
Zepbound can be a covered Part D drug in 2027 when it treats moderate to severe sleep apnea in adults with obesity, and those costs count toward the $2,400 cap. Weight-loss-only use goes to the $50 Bridge, and only in KwikPen form. Check each plan’s formulary listing and prior authorization rules for Zepbound before you pick a plan.
We do not offer every plan available in your area. Any information we provide is limited to those plans we do offer in your area. Please contact Medicare.gov or 1-800-MEDICARE (TTY 1-877-486-2048) to get information on all of your options.
Frequently Asked Questions
➤ Can I use Zepbound vials with Medicare in 2027?
Not through the Bridge, which accepts only the KwikPen. A Part D plan may list vials for sleep apnea, depending on the plan, so check the formulary.
➤ Does a mild sleep apnea diagnosis qualify?
The FDA approval covers moderate to severe obstructive sleep apnea. A mild finding usually will not meet a plan’s prior authorization criteria.
➤ If I have sleep apnea, can I choose the $50 Bridge instead?
No. Medicare excludes people with moderate to severe sleep apnea from the Bridge because a Part D plan may already cover Zepbound for them.
➤ Is Mounjaro the same as Zepbound for coverage?
Both are tirzepatide, but Mounjaro is approved for type 2 diabetes. Plans may cover Mounjaro for diabetes and Zepbound for sleep apnea under separate listings.
➤ Will Extra Help lower my Zepbound cost?
It can when a Part D plan covers Zepbound for sleep apnea. It cannot lower the $50 Bridge copay.
➤ Does Zepbound count toward the $2,400 cap?
Yes, when your plan covers it for sleep apnea. Bridge copays for weight loss do not count.
➤ Do I need a new approval if my Zepbound dose goes up?
Under the Bridge, refills of the same drug do not need a new approval even with a dose change. Plans may set their own renewal rules for covered sleep apnea use.
➤ Is Zepbound covered by Original Medicare Part B?
No. Zepbound is a self-injected drug filled at a pharmacy, so it falls under Part D or a Medicare Advantage plan with drug coverage.
ZRN Health & Financial Services, LLC, a Texas limited liability company.
Begin Choosing your plan
Advertisement
CALL TO SPEAK WITH A LICENSED INSURANCE AGENT
Advertisement